Iv%2525252525252525252525252520dexamethasone

# IV Dexamethasone ## Overview Dexamethasone is a potent synthetic glucocorticoid with negligible mineralocorticoid activity. It possesses profound anti-inflammatory and immunosuppressive properties. It has a long biological half-life (36–72 hours). ## Primary Indications * Cerebral edema (associated with neoplasms or neurosurgery) * Severe allergic reactions (anaphylaxis adjuvant) * Acute asthma exacerbations * Croup (laryngotracheobronchitis) * Chemotherapy-induced nausea and vomiting (CINV) prophylaxis * Bacterial meningitis (adjunct to antibiotics) ## Adult Dosing * **Cerebral Edema:** 10 mg IV load, followed by 4 mg IV every 6 hours. * **CINV Prophylaxis:** 8–20 mg IV once before chemotherapy. * **Bacterial Meningitis:** 10 mg IV every 6 hours for 4 days (start with or before first antibiotic dose). * **Acute Asthma:** 4–20 mg IV/PO (dose depends on clinical severity and institutional protocols). ## Pediatric Dosing * **Croup:** 0.15–0.6 mg/kg IV once (maximum 10 mg). * **Bacterial Meningitis:** 0.15 mg/kg IV every 6 hours for 2–4 days. * **CINV Prophylaxis:** 0.25–0.5 mg/kg (maximum 10–20 mg) IV once. * **Note:** Always verify dosing against local pediatric protocols (e.g., Harriet Lane or unit-specific guidelines). ## Dose Adjustments * **Hepatic Impairment:** No standard adjustment, but monitor for increased effect/side effects. * **Renal Impairment:** No dose adjustment required. * **Long-term use:** Must be tapered to avoid hypothalamic-pituitary-adrenal (HPA) axis suppression. ## Contraindications * Systemic fungal infections. * Known hypersensitivity to dexamethasone or components. * Systemic administration of live or live-attenuated vaccines in immunocompromised patients. ## Adverse Effects * **Common:** Hyperglycemia/insulin resistance, insomnia, mood changes/psychosis, fluid retention, hypertension. * **Serious:** GI ulceration/perforation, delayed wound healing, immunosuppression (increased infection risk), HPA axis suppression, secondary adrenal insufficiency. ## Key Drug Interactions * **CYP3A4 Inducers (e.g., Phenytoin, Rifampin, Carbamazepine):** Decrease dexamethasone efficacy. * **CYP3A4 Inhibitors (e.g., Ketoconazole, Ritonavir):** Increase dexamethasone exposure. * **NSAIDs/Aspirin:** Increased risk of gastrointestinal ulceration. * **Warfarin:** Variable effect on INR; monitor closely. ## Monitoring * Baseline and periodic blood glucose (especially in patients with diabetes). * Blood pressure. * Signs/symptoms of infection. * Electrolytes (hypokalemia risk). * Neuropsychiatric symptoms. ## Clinical Pearls * **Timing is critical in meningitis:** Administer 15–20 minutes before or concurrent with antibiotics to blunt the inflammatory response from bacterial lysis. * **Hyperglycemia:** Even single doses can cause significant spikes in blood glucose, particularly in patients with diabetes or those on high-dose regimens. * **Parenteral to Oral:** Dexamethasone has high oral bioavailability; switch to oral therapy as soon as clinically feasible. * **IV Administration:** Can be given IV push undiluted; administer over at least 1–2 minutes to avoid perineal burning or systemic reactions. *** *Disclaimer: This information is for educational purposes only. Clinical dosing may vary significantly based on institutional protocols, patient-specific factors (e.g., weight, age, comorbidities), and product formulation. Always verify current prescribing information and institutional guidelines before administering any medication.*